<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Mon, 01 Jun 2026 08:02:13 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Athabasca Oil closes $500 million credit facility, boosts liquidity to $870 million</title>
   <link>http://www.streetinsider.com/Corporate+News/Athabasca+Oil+closes+%24500+million+credit+facility%2C+boosts+liquidity+to+%24870+million/26579617.html</link>
   <description>

&lt;p&gt;Athabasca Oil Corporation (TSX: ATH) closed a new $500 million covenant-based credit facility with Canadian banks, the company announced. The facility has a four-year term ending in May 2030 and includes annual extension rights.&lt;/p&gt;

&lt;p&gt;Duvernay Energy, a subsidiary in which Athabasca holds a 70% equity interest, also closed an expanded $75 million reserve-based credit facility. Combined with existing resources, the company's consolidated liquidity reaches approximately $870 million.&lt;/p&gt;

&lt;p&gt;The Calgary-based energy company reported having $60 million in net cash and $290 million in cash as of March 31, 2026, according to the press release statement.&lt;/p&gt;

&lt;p&gt;Athabasca indicated the new credit facilities support its thermal</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/Athabasca+Oil+closes+%24500+million+credit+facility%2C+boosts+liquidity+to+%24870+million/26579617.html</guid>
   <pubDate>Mon, 01 Jun 2026 08:02:13 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08294420</category>
   	  </item>
  <item>
   <title>Athabasca Oil closes $500 million credit facility, boosts liquidity to $870 million</title>
   <link>http://www.streetinsider.com/Corporate+News/Athabasca+Oil+closes+%24500+million+credit+facility%2C+boosts+liquidity+to+%24870+million/26579617.html</link>
   <description>

&lt;p&gt;Athabasca Oil Corporation (TSX: ATH) closed a new $500 million covenant-based credit facility with Canadian banks, the company announced. The facility has a four-year term ending in May 2030 and includes annual extension rights.&lt;/p&gt;

&lt;p&gt;Duvernay Energy, a subsidiary in which Athabasca holds a 70% equity interest, also closed an expanded $75 million reserve-based credit facility. Combined with existing resources, the company's consolidated liquidity reaches approximately $870 million.&lt;/p&gt;

&lt;p&gt;The Calgary-based energy company reported having $60 million in net cash and $290 million in cash as of March 31, 2026, according to the press release statement.&lt;/p&gt;

&lt;p&gt;Athabasca indicated the new credit facilities support its thermal</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/Athabasca+Oil+closes+%24500+million+credit+facility%2C+boosts+liquidity+to+%24870+million/26579617.html</guid>
   <pubDate>Mon, 01 Jun 2026 08:02:13 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08294420</category>
   	  </item>
  <item>
   <title>Athabasca Oil Corporation Announces New $500 Million Four-Year Credit Facility and Expanded Duvernay Energy Credit Facility</title>
   <link>http://www.streetinsider.com/Press+Releases/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;CALGARY, Alberta, June  01, 2026  (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) has closed a new $500 million covenant-based credit facility with the Canadian bank market. The facility has a four-year term to May 2030 and includes annual extension rights. Duvernay Energy has also closed an upsized $75 million reserve-based credit facility. Pro forma for the new facilities, consolidated liquidity is approximately $870 million.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The new credit facilities enhance Athabasca’s capital structure with expanded liquidity, enhanced durability and a lower cost of capital. The pro forma capital structure supports the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</guid>
   <pubDate>Mon, 01 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08294420</category>
   	  </item>
  <item>
   <title>Athabasca Oil Corporation Announces New $500 Million Four-Year Credit Facility and Expanded Duvernay Energy Credit Facility</title>
   <link>http://www.streetinsider.com/Press+Releases/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;CALGARY, Alberta, June  01, 2026  (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) has closed a new $500 million covenant-based credit facility with the Canadian bank market. The facility has a four-year term to May 2030 and includes annual extension rights. Duvernay Energy has also closed an upsized $75 million reserve-based credit facility. Pro forma for the new facilities, consolidated liquidity is approximately $870 million.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The new credit facilities enhance Athabasca’s capital structure with expanded liquidity, enhanced durability and a lower cost of capital. The pro forma capital structure supports the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</guid>
   <pubDate>Mon, 01 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08294420</category>
   	  </item>
  <item>
   <title>Athabasca Oil Corporation Announces New $500 Million Four-Year Credit Facility and Expanded Duvernay Energy Credit Facility</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;CALGARY, Alberta, June  01, 2026  (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) has closed a new $500 million covenant-based credit facility with the Canadian bank market. The facility has a four-year term to May 2030 and includes annual extension rights. Duvernay Energy has also closed an upsized $75 million reserve-based credit facility. Pro forma for the new facilities, consolidated liquidity is approximately $870 million.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The new credit facilities enhance Athabasca’s capital structure with expanded liquidity, enhanced durability and a lower cost of capital. The pro forma capital structure supports the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</guid>
   <pubDate>Mon, 01 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08294420</category>
   	  </item>
  <item>
   <title>Athabasca Oil Corporation Announces New $500 Million Four-Year Credit Facility and Expanded Duvernay Energy Credit Facility</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;CALGARY, Alberta, June  01, 2026  (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) has closed a new $500 million covenant-based credit facility with the Canadian bank market. The facility has a four-year term to May 2030 and includes annual extension rights. Duvernay Energy has also closed an upsized $75 million reserve-based credit facility. Pro forma for the new facilities, consolidated liquidity is approximately $870 million.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;The new credit facilities enhance Athabasca’s capital structure with expanded liquidity, enhanced durability and a lower cost of capital. The pro forma capital structure supports the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Athabasca+Oil+Corporation+Announces+New+%24500+Million+Four-Year+Credit+Facility+and+Expanded+Duvernay+Energy+Credit+Facility/26579592.html</guid>
   <pubDate>Mon, 01 Jun 2026 08:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.08294420</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics presents data supporting ATH434 Phase 3 advance in MSA</title>
   <link>http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</link>
   <description>

&lt;p&gt;Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from three medical conferences supporting the advancement of its drug candidate ATH434 into Phase 3 clinical development for Multiple System Atrophy, according to a company statement.&lt;/p&gt;

&lt;p&gt;The presentations included research from Vanderbilt University Medical Center showing that quantitative susceptibility mapping can detect progressive iron accumulation in early MSA stages. The MRI imaging approach demonstrated the ability to detect iron dysregulation before clinical diagnosis and track progression over 12 months.&lt;/p&gt;

&lt;p&gt;Results from the company's Phase 2 trial showed ATH434 slowed functional decline in MSA patients. The 50 mg twice-daily dose produced a statistically significant effect</description>
   <guid isPermaLink="true">http://www.streetinsider.com/FDA/Alterity+Therapeutics+presents+data+supporting+ATH434+Phase+3+advance+in+MSA/26517235.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy</title>
   <link>http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;MELBOURNE, Australia AND SAN FRANCISCO, May  19, 2026  (GLOBE NEWSWIRE) --   &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Alterity Therapeutics&lt;/a&gt; (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy</title>
   <link>http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;MELBOURNE, Australia AND SAN FRANCISCO, May  19, 2026  (GLOBE NEWSWIRE) --   &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Alterity Therapeutics&lt;/a&gt; (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy</title>
   <link>http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;MELBOURNE, Australia AND SAN FRANCISCO, May  19, 2026  (GLOBE NEWSWIRE) --   &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Alterity Therapeutics&lt;/a&gt; (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy</title>
   <link>http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;MELBOURNE, Australia AND SAN FRANCISCO, May  19, 2026  (GLOBE NEWSWIRE) --   &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Alterity Therapeutics&lt;/a&gt; (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
  <item>
   <title>Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy</title>
   <link>http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;– End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – &lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;MELBOURNE, Australia AND SAN FRANCISCO, May  19, 2026  (GLOBE NEWSWIRE) --   &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=4nCgxhdCsmEcuzLPUZCbuAkJ1vif4elpf2JiKMSqHRrNUxhtndtwGHhNsUZL49gtNgfMKiWetokD6ILB5F2DUV6l7x7Lkdo56LSTKgdDFhI=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Alterity Therapeutics&lt;/a&gt; (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) were delivered at three</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Data+Presentations+Support+Advancement+of+ATH434+into+Phase+3+in+Multiple+System+Atrophy/26517233.html</guid>
   <pubDate>Tue, 19 May 2026 07:25:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.19718279</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.31293549</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216778</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATH.AX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">ATHE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00573636</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00730626</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01951358</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21962133</category>
   	  </item>
 </channel>
</rss>
